Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Long-Term Investments: 2013-2025

Historic Long-Term Investments for Agios Pharmaceuticals (AGIO) over the last 12 years, with Sep 2025 value amounting to $304.3 million.

  • Agios Pharmaceuticals' Long-Term Investments fell 53.60% to $304.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $304.3 million, marking a year-over-year decrease of 53.60%. This contributed to the annual value of $638.3 million for FY2024, which is 2068.58% up from last year.
  • Agios Pharmaceuticals' Long-Term Investments amounted to $304.3 million in Q3 2025, which was down 24.00% from $400.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Long-Term Investments' 5-year high stood at $655.9 million during Q3 2024, with a 5-year trough of $21.6 million in Q1 2021.
  • Over the past 3 years, Agios Pharmaceuticals' median Long-Term Investments value was $271.7 million (recorded in 2023), while the average stood at $317.5 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Long-Term Investments plummeted by 90.62% in 2023 and then soared by 2,068.58% in 2024.
  • Agios Pharmaceuticals' Long-Term Investments (Quarterly) stood at $266.4 million in 2021, then rose by 17.83% to $313.9 million in 2022, then plummeted by 90.62% to $29.4 million in 2023, then skyrocketed by 2,068.58% to $638.3 million in 2024, then tumbled by 53.60% to $304.3 million in 2025.
  • Its Long-Term Investments was $304.3 million in Q3 2025, compared to $400.5 million in Q2 2025 and $531.3 million in Q1 2025.